Physician profile
Amy E Mclaurin
NPI 1194710855
$5,073.45
in general payments reported to CMS, 2019-2025
33 companies · $590 in 2025
The $590 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $402 · 2021: $883 · 2022: $1,063 · 2023: $834 · 2024: $624 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,680.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $562.69 | 2019-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $273.62 | 2019-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $265.47 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $245.43 | 2020-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.52 | 2019-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $213.75 | 2021-2023 | Recorlev |
| Abbott Laboratories | $199.89 | 2021-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $185.83 | 2021-2024 | Minimed 780g, Minimed 770g |
| Astrazeneca Pharmaceuticals LP | $157.58 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $128.93 | 2019-2023 | |
| Valeritas, INC. | $89.74 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $83.32 | 2023-2025 | Baqsimi |
| Cequr Corporation | $81.07 | 2022-2025 | Cequr Simplicity |
| Dexcom, INC. | $70.55 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $63.97 | 2019-2021 | |
| Mannkind Corporation | $59.82 | 2021-2024 | |
| Ibsa Pharma INC. | $58.91 | 2021-2023 | Tirosint, Licart |
| Abbvie INC. | $47.79 | 2022-2023 | |
| Beta Bionics, INC. | $45.73 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Alfasigma USA, INC. | $38.73 | 2021 | |
| Shire North American Group INC | $38.58 | 2019 | |
| Nevro Corp. | $36.16 | 2024 | Senza |
| Bayer Healthcare Pharmaceuticals INC. | $34.72 | 2023-2025 | |
| Medtronic Minimed, INC. | $31.91 | 2019 | |
| Ascendis Pharma Endocrinology INC | $20.73 | 2023 | |
| Amryt Pharma Holdings LTD | $19.03 | 2021 | |
| Grt US Holding, INC. | $18.32 | 2022 | |
| Merck Sharp & Dohme LLC | $17.91 | 2019 | |
| Insulet Corporation | $17.37 | 2022 | |
| Amneal Pharmaceuticals LLC | $16.53 | 2023 | Unithroid |
| Senseonics, Incorporated | $14.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Mclaurin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.